Trouble viewing this email? Open in a browser.
 

Since COVID-19 first emerged as a global pandemic, the pharmaceutical industry has risen to meet the virus’ related challenges from a prevention as well as a treatment perspective. Much of what we know today about the COVID-19 disease course has come from data collected from some of the most severely impacted patients – those who require hospitalization.

In an effort to better understand the impact of the pandemic on people at the community level, IQVIA launched the COVID Active Research Experience (CARE) Project in April 2020.

HealthEconomics.Com’s Dr. Patti Peeples interviews Nancy A. Dreyer, MPH, PhD, FISPE, Chief Scientific Officer, IQVIA Real World Solutions, to discuss early insights and lessons learned since launching the CARE Registry.

Patti Peeples, RPh, PhD
CEO, HealthEconomics.Com and
VP, Evidence and Content, Scientist.Com
Nancy A. Dreyer, MPH, PhD, FISPE
Chief Scientific Officer
IQVIA Real World Solutions

In this blog, read the interview and listen to video clips where Dr. Dreyer describes:

  • How IQVIA used its pandemic experience and capabilities to rapidly develop and launch the CARE Registry
  • Major building blocks and primary research objectives
  • How patient-reported data is linked with other secondary sources for richer insights
  • FDA collaboration and agile on-demand analytics from the CARE Registry

 
Reserve your spot for this upcoming webinar:
 

In the past you have provided HealthEconomics.Com with your email address. Occasionally you will receive brief announcements on products, services, news and jobs from HealthEconomics.Com or our Partners.

If you don't wish to receive these announcements, you may immediately unsubscribe from this list here, or send your request in writing to HealthEconomics.Com, 1327 Walnut, Jacksonville, FL, 32206. Read more about our privacy policy here. You may also request a copy in writing using the address above.
 

To ensure you continue to receive emails from HealthEconomics.Com, please click here.